Teacher Retirement System of Texas Sells 3,342 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Teacher Retirement System of Texas cut its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,756 shares of the biotechnology company’s stock after selling 3,342 shares during the period. Teacher Retirement System of Texas’ holdings in Aurinia Pharmaceuticals were worth $263,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $215,000. Cibc World Markets Corp acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $113,000. Intech Investment Management LLC increased its holdings in Aurinia Pharmaceuticals by 55.7% during the fourth quarter. Intech Investment Management LLC now owns 55,623 shares of the biotechnology company’s stock worth $499,000 after buying an additional 19,905 shares during the last quarter. Virtu Financial LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $96,000. Finally, American Century Companies Inc. increased its holdings in Aurinia Pharmaceuticals by 124.2% during the fourth quarter. American Century Companies Inc. now owns 171,590 shares of the biotechnology company’s stock worth $1,541,000 after buying an additional 95,066 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $8.63 on Friday. The business has a 50 day moving average of $8.15 and a 200-day moving average of $8.07. Aurinia Pharmaceuticals Inc has a 1 year low of $5.20 and a 1 year high of $10.67. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.93 and a quick ratio of 5.26. The company has a market capitalization of $1.17 billion, a P/E ratio of 30.82 and a beta of 1.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.08. The company had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.